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Abstract
Small bowel capsule endoscopy (SBCE) can be complementary to histological assessment of celiac disease (CD) and serology
negative villous atrophy (SNVA). Determining the severity of disease on SBCE using statistical machine learning methods can
be useful in the follow up of patients. SBCE can play an additional role in differentiating between CD and SNVA. De-identified
SBCEs of patients with CD and SNVAwere included. Probabilistic analysis of features on SBCEwere used to predict severity of
duodenal histology and to distinguish between CD and SNVA. Patients with higher Marsh scores were more likely to have a
positive SBCE and a continuous distribution of macroscopic features of disease than those with lower Marsh scores. The same
pattern was also true for patients with CD when compared to patients with SNVA. The validation accuracy when predicting the
severity of Marsh scores and when distinguishing between CD and SNVA was 69.1% in both cases. When the proportions of
each SBCE class group within the dataset were included in the classification model, to distinguish between the two pathologies,
the validation accuracy increased to 75.3%. The findings of this work suggest that by using features of CD and SNVA on SBCE,
predictions can be made of the type of pathology and the severity of disease.
Keywords Celiac disease . Seronegative villous atrophy . Probabilistic analysis . Small bowel capsule endoscopy . Duodenal
histology
Introduction
Currently, the gold standard for the diagnosis of celiac disease
(CD) and seronegative villous atrophy (SNVA) is based on
duodenal histology [1]. Apart from the invasive nature of a
gastroduodenoscopy, histological diagnosis can be flawed with
errors. Unless an appropriate number of biopsies are taken and
the samples are properly oriented [2] (at least four biopsies,
including a biopsy from the duodenal bulb [1, 2]) a false neg-
ative result can occur. This is mainly because the mucosal dis-
tribution of CD is patchy [3–5]. Undiagnosed CD has long-
term implications such as osteoporosis, iron deficiency anae-
mia, refractory celiac disease and SB malignancy [6].
CD and SNVA are histologically similar [7] and sometimes
it is difficult to make a distinction between the two conditions
based on other clinical and serological tests. Small bowel cap-
sule endoscopy (SBCE) is carried out in patients with SNVA
to assess for features of CD and to rule out other causes of
villous atrophy [8]. Differentiating between CD and SNVA is
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important because of the different management these patients
require. Patients with SNVA of unknown cause have been
shown to respond to immunosuppressive therapy [9]. The
mainstay of management of patients with CD is gluten-free
diet (GFD) [10].
Determining severity of CD can be useful in the follow-up
of patients as this enables comparison to be made [11].
Improving the diagnostic yield of SBCE through machine
learning methods can help overcome some of these pitfalls
in the diagnosis of CD and SNVA.
Machine learning for the detection of pathology on SBCEs
has been previously explored, including to quantify aspects of
macroscopic features of CD [12], for the detection of
angieoectasias on SBCE [13], in the delineation of small bow-
el (SB) tumours [14], the recognition of inflammatory changes
on SBCE [15] and even in the detection and assessment of
colonic polyps on colon capsule endoscopy [16]. These stud-
ies have a common aim: to improve the delineation of pathol-
ogy on SBCE. There is however, no literature on the use of
machine learning methods to improve on the current reported
sensitivities in the detection of pathology on SBCE based on
human performance.
One aim was to assess whether a probabilistic model could
be used to predict severity of duodenal histology in patients
with CD and SNVA by considering features on SBCE.
Another aim was to assess whether a similar model could be
used to predict the type of disease (CD or SNVA) through
macroscopic features on SBCE.
Methodology
Study design and patients
Patients with newly diagnosed and established CD and SNVA
were included in this study over a one-year period from a
tertiary centre for the management of CD. All patients had a
confirmative diagnosis of CD or SNVA from serology and
histology. Patients with SNVA had negative CD serology
and were not on GFD at the time of histological diagnosis.
They underwent extensive investigations to rule out other
causes of SNVA such as inflammatory or infective conditions
[9, 17]. All patients had a gastroduodenoscopy within two
weeks from SBCE for duodenal histology and contemporary
CD serology was checked. They underwent a SBCE to assess
severity of disease, to rule out complications and to exclude
other causes for SNVA such as Crohn’s disease.
SBCEs were de-identified and read by two expert re-
viewers (more than 300 capsules per year) who were blinded
to each other’s findings, the indication for SBCE and the his-
tology result from duodenal biopsies. To increase the size and
variation, patients were considered as separate participants in
the study if their SBCE was read differently by the two
reviewers. After including the additional readings, the dataset
included 81 sets of features (i.e. readings), corresponding to
72 original patients. This allowed for a larger dataset to be
studied.
Duodenal histology
At least two biopsies from the duodenal bulb and four biopsies
from the second part of the duodenum were taken during
gastroduodenoscopy. The histology was then classified ac-
cording to the modified Marsh Criteria which reflects severity
of changes [18] (Table 1). All histological samples were
reviewed by two expert histopathologists. In the case of dis-
crepancy, a third histopathologist was involved.
Small bowel capsule endoscopy
All patients underwent SBCE using Pillcam SB3 (Medtronic,
Minneapolis, USA) [19].
Features reviewed included: total area affected, patchy
/continuous pattern and macroscopic features of CD: mosaic
pattern, fissuring of mucosa, scalloping of folds, villous atro-
phy, nodularity of mucosa and presence of ulcers (Fig. 1).
Ethical considerations
The study protocol was approved by the Yorkshire and the
Humber Research Ethics committee (IRAS 232382) and reg-
istered with the local research and development department of
Sheffield Teaching Hospital NHS Foundation Trust under the
registration number STH 19998. All SBCEs used in this study
were de-identified. No additional consent was required for the
study with the use of de-identified videos as assessed and
approved formally by the Research Ethics Committee.
Capsule endoscopy features
CD on SBCE was represented by nine features, {f1,…, f9}.
SBCE ¼ f 1;…; f 9f g ð1Þ
Each feature fi was considered to be a categorical variable,
with possible values fi ∈ {1,…,Ki}. These corresponded to
the associated condition of that feature; thus, fi ∈ {1,…,
Ki} (Table 2).
Target predictions
The data were used to build two predictive models. The class
associated with each patient was defined by the value of the
variable c. The first model predicted mild (c = 1) or severe
Marsh scores (c = 2). The aim of the second model was to
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Fig. 1 (a) fissuring of folds, (b) scalloping of folds, (c) villous atrophy, (d) mosaic pattern, (e) nodularity and (f) ulcers
Table 1 Marsh classification of
histological changes of celiac
disease; *IEL: intraepithelial
lymphocytes
Marsh
Type
IEL* / 100 enterocytes –
jejunum
IEL / 100 enterocytes -
duodenum
Crypt
hyperplasia
Villi
0 <40 <30 Normal Normal
1 >40 >30 Normal Normal
2 >40 >30 Increased Normal
3a >40 >30 Increased Mild atrophy
3b >40 >30 Increased Marked
atrophy
3c >40 >30 Increased Complete
atrophy
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differentiate between patients with SNVA (c = 1), and CD
(c = 2). Two, two-class classifiers were defined, where
c ∈ {1, 2} (Tables 3 and 4).
Probabilistic analysis of features
Following a probabilistic approach, each feature fi was con-
sidered to be categorically distributed,
p f i ¼ kjcð Þ ¼ Cat f ið jλi

ð2Þ
The parameter λi can be considered to be a histogram over
the K possible conditions for the feature fi (in the class c);
therefore, k ∈ {1,…,K} and λi = {λi1,…, λiK}. Specifically,
the probability of condition k was,
p f i ¼ kð Þ ¼ λik ð3Þ
In words, p(fi = k| c) was the likelihood that the condition of
feature fi was equal to k, given the class c.Each feature was
considered to be conditionally independent. This assumption
is appropriate for smaller datasets, as there are less parameters
to learn from the data. The assumption of conditional inde-
pendence (between features) is common for Naïve Bayes clas-
sification, which is shown to be appropriate in many applica-
tions, even if correlation between the features is expected [20].
The likelihood of a SBCE given the class cwas the product of
the likelihoods of its corresponding features,
p SBCEjcð Þ ¼ ∏
9
i¼1
p f i ¼ kjcð Þ ð4Þ
such that p(SBCE| c) was the likelihood of observing a SBCE,
given the patient was in class c. For example, the likelihood of
a given SBCE feature-set, given that the patient was in the
severe Marsh score group.
To inform feature analysis, and to make predictions, the
parameters of the distribution (for each feature) were learnt
Table 2 SBCE feature
descriptions Feature, fi Outcome, (k),
area affected, (f1) normal (k = 1),
proximal & beyond (k = 2)
normal/patchy/continuous, (f2) normal (k = 1),
patchy (k = 2),
continuous (k = 3)
mosaic pattern, (f3) absent (k = 1),
present (k = 2)
fissuring, (f4) absent (k = 1),
present (k = 2)
scalloping, (f5) absent (k = 1),
present (k = 2)
villous atrophy, (f6) absent (k = 1),
present (k = 2),
nodularity, (f7) absent (k = 1),
present (k = 2)
ulcers, (f8) absent (k = 1),
present (k = 2)
% length of abnormal small bowel mucosa, (f9) <50% (k = 1),
> 50% (k = 2)
Table 3 Mild vs Severe Marsh Scores
Class, c Description Number of Readings
c = 1 Mild Marsh scores
(Marsh score 0, 1, 2)
31
c = 2 Severe Marsh scores
(Marsh score 3a, 3b, 3c)
50
Table 4 CD (celiac disease) vs SNVA (seronegative villous atrophy)
Class, c Description Number of Readings
c = 1 SNVA 18
c = 2 CD 63
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from the available data. In this work, a Bayesian estimate of
the parameters was used, to mitigate overtraining, and account
for the zero-count problem [20, 21]. Additionally, a Bayesian
approach leads to distributions over the predicted values,
allowing for the uncertainty associated with predictions to be
approximated. To calculate Bayesian estimates, a prior distri-
bution was placed over the parameters of the categorical dis-
tribution, λi, for each feature. The parameters were then
marginalised out (from the model) by integration. An appro-
priate prior was the Dirichlet distribution, as it was compatible
to and conjugate with the categorical distribution [21].
Conjugacy is desirable, as it leads to tractable solutions (the
functional form of the posterior distribution will be the same
as the prior). The distribution is specified by,
p λið Þ ¼ Dir λijαð Þ ð5Þ
α ¼ α1;…;αKf g ð6Þ
The parameters of the Dirichlet distribution, α, were set to
1 (for conditions 1 to κ) for each feature. In terms of
regularisation, this corresponded to add-one or Laplace
smoothing [20]. As discussed, the effects of the parameters
were then integrated out, to provide the posterior-predictive
distribution. In this case, this was a posterior-predictive
likelihood,
p f i ¼ kjcð Þ ¼ ∫p f ijc;λið Þp λið Þdλ ð7Þ
p f i ¼ kjcð Þ ¼
N k þ αkð Þ
N þ ∑Kk¼1αk
ð8Þ
N was considered to be the total number of patients and Nk
was the number of patients (in class c), with the value k for the
feature fi. The likelihood p(fi| c) was the (estimated) proportion
of the patients in class c with condition k for feature fi; for
example, the proportion of patients in the dataset with a severe
Marsh score (c = 2), who showed (k = 2) scalloping (f5).
Results
Characteristics of the cohort studied
Seventy-two patients (45; 62.5% females, mean age 52.5 ±
16.6 years) were included in this study. Patients had a diag-
nosis of CD (51, 70.8%) or SNVA (21, 29.2%). Marsh histol-
ogy is shown in Table 5. A small proportion of patients (n =
14; 19%) had extensive abnormal small bowel mucosa
beyond the proximal area. Seventeen patients (24%) had a
normal SBCE. Patients had the following features of CD on
SBCE: 30 (42%) scalloping, 42 (58%) fissuring, 38 (53%)
mosaicism, 14 (19%) villous atrophy, 12 (17%) nodularity,
2 (3%) ulcers (Table 6).
Feature analysis–severity of marsh classification of
disease
The posterior-predictive likelihoods for the features associated
with mild vs severe Marsh scores are illustrated in Fig. 2. The
likelihoods can be interpreted as the histogram over the pos-
sible conditions for each feature, given the class of patients,
and the information in all the available data. The likelihoods
showed that all features (other than f8 for the Marsh score
model) were likely to represent more severe disease, i.e. k >
1, for:
& severe Marsh scores (rather than mild)
& CD (rather than SNVA).
Patients with higher Marsh scores were more likely to have
a positive SBCE and a continuous distribution of macroscopic
features (Fig. 2). Features including mosaic pattern, fissuring
and scalloping of folds were indicative of a more severe
Marsh classification. Villous atrophy and nodularity of muco-
sa were more common in patients with severe Marsh scores
but the difference was not distinct. Ulcers were present in a
small number of patients, and frequencies were similar in both
groups. Overall, most patients had less than 50% of the SB
involved, and those with more severe Marsh scores had more
extensive SB involvement.
Feature analysis – Type of disease (SNVA or CD)
The posterior-predictive likelihoods for SNVA and CD are
shown in Fig. 3. Again, the likelihoods can be interpreted as
the histogram over the possible conditions for each feature,
given the class of patients, and the information in all the avail-
able data. Fig. 3 illustrates that patients with CD were more
likely to have a positive SBCE than those with SNVA.
Table 5 Marsh
classification of disease Marsh score N (%)
0 9 (12.5)
1 15 (20.8)
2 3 (4.2)
3a 8 (11.1)
3b 19 (26.4)
3c 18 (25.0)
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Patients with CD were more likely to have a continuous dis-
tribution of features. Patients with SNVA were more likely to
have patchy disease. Features such as mosaic pattern of the
mucosa, fissuring of folds, scalloping, villous atrophy and
nodularity of mucosa were more likely to be present in pa-
tients with CD than patients with SNVA. Patients with CD
were more likely to have extensive SB involvement.
Predictive model: Maximum-likelihood
Amaximum likelihood approach was used to define a model for
prediction. Specifically, the predicted class, bc* is the class with
the maximum posterior-predictive likelihood for the SBCE∗,
bc* ¼ argmaxc∈ 1;2f g p SBCE*
 c
 o
ð9Þ
The performance of each classifier was assessed using
Leave-One-Out cross-validation (LOOCV) [22]. This in-
volved learning the parameters of the likelihood model
(Eq. 8) with all of the available data and excluding one patient
(the validation data). The model was then used to predict the
class of the single, held-out patient, and a score was recorded.
The score was considered unity if the patient was successfully
classified and zero if the patient was misclassified. This pro-
cess was repeated, such that all 81 SBCE readings were held
out for validation in turn. Finally, the score over the whole
data set was presented as a (percentage) accuracy.
Following LOOCV, the validation accuracy was 69.1%
when predicting the severity of the Marsh score (Table 3)
and when distinguishing between CD and SNVA (Table 4).
Predictive model: Naïve Bayes
To estimate the probability of each class given the SBCE of a
patient, the distribution over c could be estimated and included
in the model. To include this information, p(c) was estimated
from the data. In other words, the probability of observing a
class, c, was estimated, given the number of times it occurred
in the dataset (in a similar manner to the feature analysis).
Therefore,
p cð Þ ¼ Cat cjπð Þ ð10Þ
The parameter π was considered to be a histogram over the
two possible classes (for each predictor), c ∈ {1, 2}.Thus,
π = {π1, π2}, and,
p c ¼ ið Þ ¼ πi ð11Þ
Again, a Dirichlet prior was placed over π, and the α pa-
rameter was set to a vector of ones, corresponding to add-one
(Laplace) smoothing. The marginal probability over classes
could then be estimated by,
p cð Þ ¼
N c þ 1ð Þ
N þ 2
ð12Þ
Note, N was the total number of SBCE readings, and
Nc was the number of patients in class c. A probabilistic clas-
sifier could then be defined using Bayes rule [20], which was
used to define a posterior-predictive distribution over the class
groups, given the features from the SBCE of a patient,
p c*jSBCE*
 
¼
p SBCE*j c*
 
p c*
 
∑2c
*
¼1p SBCE*j c*
 
p c*
  ð13Þ
Therefore, p(c∗| SBCE∗) was a two-dimensional histogram,
corresponding to the probability of a patient belonging to:
& mild Marsh scores or severe Marsh scores;
& SNVA or CD.
Table 6 Features of celiac disease on SBCE
Feature of CD* on SBCE** Scalloping
n (%)
Fissuring
n (%)
Mosaicism
n (%)
Villous atrophy
n (%)
Nodularity
n (%)
Ulcers
n (%)
Absence of features
n (%)***
30 (42) 42 (58) 38 (53) 14 (19) 12 (17) 2 (3) 17 (24)
Extent of abnormal small bowel mucosa Proximal
n (%)
Beyond proximal
n (%)
Normal
n (%)
41 (57) 14 (19) 17 (24)
Patchy / continuous pattern /normal Patchy
n (%)
Continuous
n (%)
Normal
n (%)
8 (11) 47 (65) 17 (24)
*Celiac disease
**Small bowel capsule endoscopy
***Features do not add up to 100% as each patient could have more than one feature of celiac disease on small bowel capsule endoscopy
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Importantly, the success of this approach requires that
the proportion of patients in each class is representative
of future data.
Firstly, the estimate of p(c) was included in the mod-
el used to predict Marsh scores. In this case, the
LOOCV accuracy decreased significantly to 56.8%.
The probability p(c) was also included into the model
to predict differentiation between classes of SNVA and
CD. For this predictor, the validation accuracy increased
to 75.3%.
Discussion
This is the first study that demonstrates how macroscopic
features of CD/SNVA on SBCE can help predict the severity
of disease. It is also the first study to show that pattern recog-
nition on SBCE can help distinguish between CD and SNVA.
In patients with newly-diagnosed CD, severity of duodenal
histology at the time of diagnosis can be predictive of histo-
logical recovery at one year from diagnosis [23]. In
established CD, incomplete mucosal recovery can also be
Fig. 2 Histograms learnt from the data, showing the likelihood of each feature, given the class of patients corresponding to: mild (white), or severe
(black) Marsh score
Page 7 of 10 195J Med Syst (2020) 44: 195
predictive of complications [24]. Predicting severity of disease
by considering features on SBCE can help physicians assess
the risk of complications or predict the time needed for muco-
sal recovery. Quantifying severity of CD on SBCE is useful in
the follow up of patients with CD, as this enables a compari-
son to be made between SBCEs before and after treatment is
commenced [11, 25]. Patients with persistently similar fea-
tures on follow up SBCE can be managed more aggressively
by adding immunosuppressants. In this study, patients with
higher Marsh scores were more likely to have macroscopic
evidence of CD and for a longer distribution on SBCE.
There are several causes of SNVA such as medications,
infections and inflammatory conditions [17]. These can cause
histological changes that can mimic CD. CD and SNVA can-
not be distinguished by considering histology only, but by
taking into consideration other parameters such as human leu-
cocyte antigen genotype, CD serology and exclusion of other
causes of villous atrophy. Recognition of differences in pat-
terns of disease in the SB for both conditions can enable
SBCE to play an additional role in their distinction.
Differentiating between both conditions is crucial because of
different management [26] and also because of the higher
Fig. 3 Histograms learnt from the data, showing the likelihood of each feature, given the class corresponding to: serology negative villous atrophy
(white), or celiac disease (black)
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mortality associated with SNVA than with CD [27]. In the
second model, that predicted the distinction between CD and
SNVA, patients with CDweremore likely to havemacroscop-
ic evidence of disease on SBCE than patients with SNVA.
The sensitivity of SBCE to detect features of CD varies
between 71 and 93% [25, 28–33]. For both models, a
LOOCV validation accuracy of 69.1% was achieved using a
maximum (posterior-predictive) likelihood approach. While
these accuracies may seem low, the performance is near the
quoted sensitivity of the SBCE, which effectively limits the
classification accuracy of the model.
The reliability of the probabilistic model relies on the as-
sumption that the number of patients in each class is represen-
tative of future data. When the proportion of patients was
taken into consideration in the severity Marsh score model,
the LOOCV accuracy decreased to 56.8%; therefore, it is as-
sumed that the available data were not representative of the
expected distribution over the class labels p(c) for marsh score
subgroups (mild / severe). For CD or SNVA, however, the
validation accuracy increased to 75.3% by including an esti-
mate of the distribution over class marginal, used to define
Naïve Bayes classifier. The performance increase for the CD
SNVA model makes sense, as the estimate of the distribution
p(c) (77.8%CD, 22.2% SNVA) was similar to that reported in
the literature (77% CD, 29% SNVA) in a group of patients
with varying villous atrophy [34].
One limitation of the study was the relatively small dataset,
however, this is one of the largest CD/SNVA SBCE dataset
compared to the current literature. Another limitation of this
study is the lack of distinction between SNVA-CD, SNVA in
patients with an unknown cause and SNVA in those with an
identifiable cause other than CD; however, further classifica-
tion into these subgroups would have rendered the groups
even smaller.
Conclusions
Using probabilistic analysis of macroscopic features on SBCE
it is suggested that more pronounced and extensive features
are present in patients with more severe Marsh scores of his-
tology and in patients with CD (as opposed to SNVA). The
findings of this work suggest that, from the available data,
SBCE features are suitable in making predictions as to wheth-
er a patient has CD or SNVA and to determine the severity of
disease. With validation on new patients, this implies that the
diagnosis of CD or SNVA and the severity of disease may be
supported by probabilistic machine learning, applied to SBCE
features.
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